Introduction
Currently about 347 million people worldwide suffer from diabetes mellitus [1] . An artificial pancreas mimicking the glucose metabolism of a healthy individual would be necessary to sufficiently normalize the glucose household of type I diabetics and to drastically reduce longterm and acute complications. In order to overcome some of the drawbacks of current glucose monitoring and insulin infusion methods, we developed an integrated catheter for continuous glucose monitoring (CGM) and simultaneous insulin delivery. A single-port body interface (Fig. 1) integrates the glucose sensor into the insulin infusion catheter, thus solving two fundamental problems. First, insertion and removal of the sensor imposes no additional burden on the patient. Second, issues regarding bio-compatibility and long-termstability are minimised, as the catheter carrying the sensor is replaced at frequent, short intervals. The sensor system consists of an optical enzymatic glucose sensor and an optical oxygen reference sensor, which compensates for oxygen fluctuations in the surrounding tissue. The phosphorescent dyes platinum(II)-mesotetra(4-fluorophenyl)tetrabenzo-porphyrin (PtTPTBPF) and platinum(II)-6-aza-13,20,27-triphenyltetra(tert-butylbenzo)porphyrin (tbutPtNTBP) are used in the glucose and reference oxygen sensor respectively (Fig. 2 ). Both dyes are excited above 600nm and emit in the nearinfrared (NIR) region ( Similar to the "Smart Tattoo"-technology described by Ballerstadt [2] and McShane [3] , the oxygen-dependent NIR-signals are detected transcutaneously. Lifetime measurements in the frequency domain are conducted with a mini-phase fluorometer comprised in the optical module.
Methods and Results
The spray-coated glucose sensors were tested in-vitro in a continuous-flow-setup regarding to their response to glucose in a range from 0 mg/dL to 360 mg/dL. Different oxygen partial pressures (pO 2 ) from 50 mmHg to 100 mmHg were tested, simulating the pO 2 -range in tissue. The non-linear response of the glucose sensor to different glucose concentrations is shown in Fig. 4 . Its response time is 60 ± 10s. The reference oxygen sensor is used for compensation of the oxygen-crosstalk of the glucose sensor. In order to be able estimate the influence of insulin infusion at the point of measurement on the glucose concentration, three sensor groups (6 sensors each) were tested in a pre-clinic in-vivo study in pigs.
-sensor group 1: no infusion -sensor group 2: insulin infusion (1.2 U/h) -sensor group 3: infusion of physiological NaClsolution (12 µL/h) Sensor data were compared to arterial blood reference glucose values, which were taken every 5min over a measurement period of 8h (Fig. 5 ). The relative prediction error sum of squares (%PRESS) was used (see Eq. 1) for quantitative comparison of the infusion effect on the three sensor groups.
(1) There are no significant differences between the three sensor groups (Tab. 1). It can therefore be concluded that insulin infusion at the place of measurement does not influence the measured glucose concentration.
Discussion
In proof-of-concept experiments it could be shown that transcutaneous read-out of the generated NIR-signals is possible and that phase fluorometry is a reliable method for continuous glucose monitoring. Furthermore the combination of CGM and simultaneous insulin infusion in a single-port-concept is feasible. Expansion to an artificial pancreas is currently being worked on. 
